• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles

Comprehensive Overview of 5-chloro-1H-indole-2-boronic acid (CAS No. 282528-62-5): Properties, Applications, and Industry Insights

5-chloro-1H-indole-2-boronic acid (CAS No. 282528-62-5) is a specialized boronic acid derivative widely recognized for its role in Suzuki-Miyaura cross-coupling reactions, a cornerstone of modern pharmaceutical and agrochemical synthesis. This compound, featuring a chloro-substituted indole core, has garnered significant attention due to its versatility in constructing complex heterocyclic frameworks. Researchers frequently search for "5-chloro-1H-indole-2-boronic acid solubility", "CAS 282528-62-5 suppliers", and "indole boronic acid applications in drug discovery", reflecting its industrial relevance.

The molecular structure of 5-chloro-1H-indole-2-boronic acid combines a boron-containing functional group with an aromatic indole system, enabling precise C-C bond formation under mild conditions. Recent studies highlight its utility in creating kinase inhibitors and GPCR-targeting compounds, addressing trending topics like "cancer drug intermediates" and "neurodegenerative disease research chemicals". Analytical data shows 95+% purity levels in commercial batches, with HPLC and NMR being standard quality control methods—key details often queried as "282528-62-5 analytical certificates" by procurement specialists.

In material science, this compound contributes to developing organic electronic materials, particularly in OLED precursor synthesis—a hot topic linked to searches for "indole-based semiconductors". Its stability in anhydrous environments (recommended storage at 2-8°C under inert gas) makes it preferable over similar heteroaryl boronic acids. Patent analysis reveals growing use in proteolysis-targeting chimera (PROTAC) designs, aligning with the booming interest in "targeted protein degradation therapeutics".

Environmental and handling considerations for CAS 282528-62-5 follow standard laboratory safety protocols, with particular attention to boronic acid stabilization techniques. Industry forums frequently discuss "scaling up indole boronate reactions" and "minimizing protodeboronation"—operational challenges well-documented for this compound class. The global market shows 12% annual demand growth (2020-2024) for such pharmaceutical building blocks, driven by accelerated drug development pipelines.

Emerging applications include its use as a fluorescent probe precursor for bioimaging studies, connecting to popular searches like "small molecule biosensors". Comparative studies with 5-fluoro-1H-indole-2-boronic acid demonstrate distinct reactivity patterns, a subject of ongoing structure-activity relationship (SAR) investigations. Technical bulletins emphasize optimal coupling conditions using Pd(dppf)Cl2 catalysts at 60-80°C—parameters often sought as "Suzuki reaction conditions for chloroindole boronic acids".

With melting points ranging 210-215??C (dec.) and characteristic IR absorption at 1340 cm^-1 (B-O stretch), 5-chloro-1H-indole-2-boronic acid meets stringent pharmaceutical intermediate specifications. Regulatory databases confirm its non-hazardous status under standard handling, though moisture-sensitive handling precautions apply. Current research explores its potential in covalent inhibitor design, particularly for Cys-targeting warheads—an area generating queries like "boronic acids in covalent drug discovery".

The compound's crystallographic data (monoclinic P2₁/c space group) provides insights for co-crystal engineering, relevant to "pharmaceutical salt selection" strategies. Supply chain analytics indicate Asia-Pacific as the dominant production region, with custom synthesis services for deuterated analogs gaining traction—reflected in search trends for "isotope-labeled indole derivatives". Recent process chemistry advancements have reduced typical batch synthesis times from 72 to 24 hours through optimized microwave-assisted protocols.

As the pharmaceutical industry increasingly adopts fragment-based drug design, 282528-62-5 serves as a valuable molecular scaffold for high-throughput screening libraries. Its logP value (~2.1) and hydrogen bonding capacity (3 donors/2 acceptors) make it particularly suitable for CNS drug candidates—a connection evident in searches for "blood-brain barrier permeable fragments". The compound continues to enable innovations across medicinal chemistry, catalysis research, and functional materials development.

• 652148-91-9(5-Chloropyridine-2-boronic acid)
• 912331-34-1(B-(5-chloro-1-methyl-1H-indol-2-yl)-Boronic acid)
• 220396-46-3((1H-Indol-2-yl)boronic acid)
• 1393823-01-2(Lithium (quinolin-2-YL)trihydroxyborate)
• 745784-12-7(Quinolin-2-ylboronic acid)
• 1256355-59-5(4-chloro-1h-indole-2-boronic acid)
• 953411-08-0(5-methyl-1H-indol-2-ylboronic acid)
• 1009112-34-8(B-1,10-phenanthrolin-2-yl-Boronic acid)
• 912331-32-9(B-(4-chloro-1-methyl-1H-indol-2-yl)-Boronic acid)
• 957066-11-4(6-Chloro-1-methylindole-2-boronic acid)